Publikationen im NUM
Hier finden Sie eine Liste der Publikationen, die im Zusammenhang mit dem Netzwerk Universitätsmedizin in der ersten und zweiten Förderphase entstanden sind.
S. Stillfried,
S. Villwock,
R. D. Bülow,
S. Djudjaj,
E. M. Buhl,
A. Maurer,
N. Ortiz-Brüchle,
P. Celec,
B. M. Klinkhammer,
D. W. Wong,
C. Cacchi,
T. Braunschweig,
R. Knüchel-Clarke,
E. Dahl and
P. Boor,
"SARS-CoV-2 RNA screening in routine pathology specimens",
Microb Biotechnol,
vol. 14,
no. 4,
pp. 1627-1641,
Jul.
2021.
| DOI: | 10.1111/1751-7915.13828 |
S. Heinemann,
A. Bludau,
H. Kaba and
et al,
"SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST",
GMS Hyg Infect Control,
vol. 16,
2021.
| DOI: | 10.3205/dgkh000402 |
S. Heinemann,
A. Bludau,
H. Kaba,
P. Knolle,
H. Grundmann and
S. Scheithauer,
"SARS-CoV-2 surveillance and testing: results of a survey from the Network of University Hospitals (NUM), B-FAST",
GMS hygiene and infection control,
vol. 16,
pp. Doc31,
2021.
Abstract:
Background: The B-FAST project of the National University Network (NUM) examines and records applied surveillance strategies implemented in hospitals i.a., to protect patients and employees from SARS-CoV-2 infection. Methods: Infection control physicians in German university hospitals (UK), as well as non-university hospitals (NUK; Bavaria, Lower Saxony) were surveyed in March 2021 regarding SARS-CoV-2 testing/surveillance strategies in a cross-sectional study using a standardized online questionnaire. The focus was on screening strategies taking into account the \textquotedbltest\textquotedbl methods used (case history, PCR, antigen, antibody test). Results: The response rate was 91.7% (33/36) in UK and 11.3%-32.2% in NUK. Almost all hospitals (95.0%) performed a symptom and exposure check and/or testing upon inpatient admission. Non-cause-related testing (screening) of health care workers in COVID wards was preferably done by PCR in UK (69.7% PCR; 12.1% antigen), while NUK (29.9% PCR; 49.3% antigen) used antigen testing more frequently. Regardless of the type of facility, about half of the respondents rated the benefit of screening higher than the effort (patients: 49%; employees: 45%). Conclusion: Testing/surveillance strategies find a high level of acceptance at German hospitals and are generally carried out in accordance with the national testing strategy with differences depending on the level of care. Hintergrund: Im „Bundesweiten Forschungsnetzwerk zur Angewandten Surveillance und Testung“ (B-FAST) werden anwendungsbezogene Strategien geprüft und erfasst, die u.a. in Krankenhäusern zum Schutz von Patient*innen und Beschäftigten vor SARS-CoV-2 implementiert wurden.Methoden: Im März 2021 wurden in einer Querschnittstudie mit einem standardisierten Online-Fragebogen die leitenden (Krankenhaus-)Hygieniker*innen in deutschen Universitätskliniken (UK), sowie Nicht-Universitätskliniken (NUK) in Bayern und Niedersachsen zu SARS-CoV-2 Test- und Surveillance-Strategien befragt. Im Fokus standen Screening-Strategien unter Berücksichtigung der eingesetzten „Test“-Methoden (Anamnese, PCR-, Antigen-, Antikörpertest).Ergebnisse: Der Rücklauf liegt bei 91,7% (33 von 36) aus den UK, bei 32,2% (37 von 115) aus den niedersächsischen NUK und bei 11,3% (30 von 265) aus den bayrischen NUK. Nahezu alle Kliniken (95,0%) führen bei der Aufnahme stationärer Patient*innen einen Symptom/Expositionscheck und/oder eine Testung durch. Das nicht-anlassbezogene Testen (Screening) von Beschäftigten im COVID-Bereich erfolgte in UK (69,7% PCR; 12,1% Antigen) bevorzugt durch PCR, während NUK (29,9% PCR; 49,3% Antigen) häufiger Antigentests einsetzten. Unabhängig von der Einrichtungsart bewerten etwa die Hälfte der Befragten den Nutzen von Screening höher als den Aufwand (bei Patient*innen 49,0%; bei Beschäftigten 45,0%).Fazit: Test- und Surveillance-Strategien finden an deutschen Kliniken hohe Akzeptanz und werden grundsätzlich in Anlehnung an die nationale Teststrategie — mit Unterschieden je nach Versorgungsstufe — durchgeführt.
| DOI: | 10.3205/dgkh000402 |
Abstract:
Background: The B-FAST project of the National University Network (NUM) examines and records applied surveillance strategies implemented in hospitals i.a., to protect patients and employees from SARS-CoV-2 infection. Methods: Infection control physicians in German university hospitals (UK), as well as non-university hospitals (NUK; Bavaria, Lower Saxony) were surveyed in March 2021 regarding SARS-CoV-2 testing/surveillance strategies in a cross-sectional study using a standardized online questionnaire. The focus was on screening strategies taking into account the \textquotedbltest\textquotedbl methods used (case history, PCR, antigen, antibody test). Results: The response rate was 91.7% (33/36) in UK and 11.3%-32.2% in NUK. Almost all hospitals (95.0%) performed a symptom and exposure check and/or testing upon inpatient admission. Non-cause-related testing (screening) of health care workers in COVID wards was preferably done by PCR in UK (69.7% PCR; 12.1% antigen), while NUK (29.9% PCR; 49.3% antigen) used antigen testing more frequently. Regardless of the type of facility, about half of the respondents rated the benefit of screening higher than the effort (patients: 49%; employees: 45%). Conclusion: Testing/surveillance strategies find a high level of acceptance at German hospitals and are generally carried out in accordance with the national testing strategy with differences depending on the level of care. Hintergrund: Im „Bundesweiten Forschungsnetzwerk zur Angewandten Surveillance und Testung“ (B-FAST) werden anwendungsbezogene Strategien geprüft und erfasst, die u.a. in Krankenhäusern zum Schutz von Patient*innen und Beschäftigten vor SARS-CoV-2 implementiert wurden.Methoden: Im März 2021 wurden in einer Querschnittstudie mit einem standardisierten Online-Fragebogen die leitenden (Krankenhaus-)Hygieniker*innen in deutschen Universitätskliniken (UK), sowie Nicht-Universitätskliniken (NUK) in Bayern und Niedersachsen zu SARS-CoV-2 Test- und Surveillance-Strategien befragt. Im Fokus standen Screening-Strategien unter Berücksichtigung der eingesetzten „Test“-Methoden (Anamnese, PCR-, Antigen-, Antikörpertest).Ergebnisse: Der Rücklauf liegt bei 91,7% (33 von 36) aus den UK, bei 32,2% (37 von 115) aus den niedersächsischen NUK und bei 11,3% (30 von 265) aus den bayrischen NUK. Nahezu alle Kliniken (95,0%) führen bei der Aufnahme stationärer Patient*innen einen Symptom/Expositionscheck und/oder eine Testung durch. Das nicht-anlassbezogene Testen (Screening) von Beschäftigten im COVID-Bereich erfolgte in UK (69,7% PCR; 12,1% Antigen) bevorzugt durch PCR, während NUK (29,9% PCR; 49,3% Antigen) häufiger Antigentests einsetzten. Unabhängig von der Einrichtungsart bewerten etwa die Hälfte der Befragten den Nutzen von Screening höher als den Aufwand (bei Patient*innen 49,0%; bei Beschäftigten 45,0%).Fazit: Test- und Surveillance-Strategien finden an deutschen Kliniken hohe Akzeptanz und werden grundsätzlich in Anlehnung an die nationale Teststrategie — mit Unterschieden je nach Versorgungsstufe — durchgeführt.
M. Hoffmann and
et al,
"SARS-CoV-2 variant B.1.617 is resistant to bamlanivimab and evades antibodies induced by infection and vaccination",
Cell Reports,
vol. 36,
pp. 109415,
2021.
| DOI: | 10.1016/j.celrep.2021.109415 |
M. Hoffmann and
et al,
"SARS-CoV-2 variants B.1.351 and P.1 escape from neutralizing antibodies",
Cell,
vol. 184,
pp. 2384-2393.e12,
2021.
| DOI: | 10.1016/j.cell.2021.03.036 |
L. Lohner,
D. Fröb,
C. Edler,
A. S. Schröder,
E. Dietz and
B. Ondruschka,
"SARS-CoV-2-assoziierte Todesfälle von erwachsenen Personen bis 50 Jahre: Eine retrospektive Auswertung der COVID-19-assoziierten Todesfälle im Jahr 2020 im Institut für Rechtsmedizin Hamburg, Deutschland [SARS-CoV-2-associated deaths in adult persons up to 50 years of age]",
Rechtsmedizin (Berl),
pp. 1-9,
2021.
N. Gassen,
J. Papies,
T. Bajaj,
J. Emanuel,
F. Dethloff and
e. a. Chua,
"SARS-CoV-2-mediated dysregulation of metabolism and autophagy uncovers host-targeting antivirals",
Nat Commun,
vol. 12,
pp. 3818,
2021.
N. Kreuzberger and
et al,
"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19",
Cochrane Database of Systematic Reviews,
vol. 9,
pp. CD013825,
2021.
| DOI: | 10.1002/14651858.CD013825.pub2 |
N. Kreuzberger,
C. Hirsch,
K. L. Chai,
E. Tomlinson,
Z. Khosravi,
M. Popp,
M. Neidhardt,
V. Piechotta,
S. Salomon,
S. J. Valk,
I. Monsef,
C. Schmaderer,
E. M. Wood,
C. So-Osman,
D. J. Roberts,
Z. McQuilten,
L. J. Estcourt and
N. Skoetz,
"SARS-CoV-2-neutralising monoclonal antibodies for treatment of COVID-19",
Cochrane Database Syst Rev,
vol. 9,
no. 9,
pp. CD013825,
2021.
| DOI: | 10.1002/14651858.CD013825.pub2 |
C. Hirsch and
et al,
"SARS-CoV-2-neutralising monoclonal antibodies to prevent COVID-19",
Cochrane Database of Systematic Reviews,
2021.
| DOI: | 10.1002/14651858.CD014945 |
K. G. Schmidt and
et al,
"SARS-CoV-2-Seronegative Subjects Target CTL Epitopes in the SARS-CoV-2 Nucleoprotein Cross-Reactive to Common Cold Coronaviruses",
Frontiers in immunology,
vol. 12,
pp. 627568,
2021.
| DOI: | 10.3389/fimmu.2021.627568 |
D. Gornyk and
et al,
"SARS-CoV-2-Seroprävalenz in Deutschland. Eine bevölkerungsbezogene sequenzielle Studie in sieben Regionen",
Dtsch Arztebl Int,
vol. 118,
pp. 824–831,
2021.
A. Klein,
F. Langenwalder,
F. Heinrich,
K. Meißner,
A. S. Schröder,
K. Püschel,
B. Ondruschka,
M. Lütgehetmann and
A. Heinemann,
"SARS-CoV2-Zufallsentdeckungen bei Hamburger Todesfällen: ein epidemiologisches Monitoring während des dynamischen Infektionsgeschehens im Frühjahr 2020 [SARS-CoV2 incidental findings among Hamburg deaths: an epidemiological monitoring during the dynamic infection event in spring 2020]",
Rechtsmedizin (Berl),
pp. 1-7,
2021.
D. Wolday,
C. M. Denkinger and
et al,
"Scaled testing for COVID-19 needs community involvement",
J Glob Health,
vol. 11,
2021.
| DOI: | 10.7189/jogh.11.03033 |
| Datei: | https://doi.org/10.7189/jogh.11.03033 |
S. Würstle,
C. D. Spinner,
F. Voit and
et al,
"Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing",
Infection,
vol. 49,
no. 5,
2021.
| DOI: | 10.1007/s15010-021-01614-9 |
S. Würstle,
C. Spinner,
F. Voit and
D. Stahl,
"Self-sampling versus health care professional-guided swab collection for SARS-CoV-2 testing",
Infection,
vol. 49,
no. 5,
2021.
| DOI: | 10.1007/s15010-021-01614-9 |
| Datei: | https://doi.org/10.1007/s15010-021-01614-9 |
J. Schmuck,
N. Hiebel,
M. Rabe,
J. Schneider,
Y. Erim,
E. Morawa,
L. Jerg-Bretzke,
P. Beschoner,
J. Hannemann,
K. Weidner,
S. Steudte-Schmiedgen,
L. Radbruch,
H. Brunsch and
F. Geiser,
"Sense of coherence, social support and religiosity as resources for medical personnel during the COVID-19 pandemic: A web-based survey among 4324 health care workers within the German Network University Medicine",
PLOS ONE,
vol. 16,
no. 7,
2021.
| DOI: | 10.1371/journal.pone.0255211 |
F. Steinbeis,
C. Thibeault,
F. Doellinger,
R. Ring,
M. Mittermaier,
C. Ruwwe-Glösenkamp,
P. Knape,
H. Meyer,
L. Lippert and
D. Stahl,
"Severity of respiratory failure and computed chest tomography in acute COVID-19 correlates with pulmonary function and respiratory symptoms after infection with SARS-CoV-2: An observational longitudinal study over 12 months",
Respir Med,
vol. 191,
pp. 106709,
2021.
| DOI: | 10.1016/j.rmed.2021.106709 |
F. Günl,
A. Mecate-Zambrano,
S. Rehländer,
S. Hinse,
S. Ludwig and
L. Brunotte,
"Shooting at a Moving Target-Effectiveness and Emerging Challenges for SARS-CoV-2 Vaccine Development",
Vaccines (Basel),
vol. 9,
2021.
J. Holz,
"Singapurs gebrochenes Versprechen",
Südostasien. Zeitschrift für Politik, Kultur, Dialog,
Feb.
2021.
D. S. Fischer and
et al,
"Single-cell RNA sequencing reveals ex vivo signatures of SARS-CoV-2-reactive T cells through 'reverse phenotyping'",
Nature Communications,
vol. 12,
pp. 4515,
2021.
| DOI: | 10.1038/s41467-021-24730-4 |
A. Wulff,
C. Baier,
M. Marschollek and
et al,
"SmICS: Eine smarte Lösung zur automatisierten Ausbruchserkennung im Krankenhaus",
Gesundhyte,
vol. 14,
2021.
| Datei: |  https://www.systembiologie.de/lw_resource/datapool/systemfiles/elements/files/D344CA9772B73013E0537E695E8653F9/live/document/PTJ-009_gesundhyte_14_2021_dt_WEB-ISSN_2702-2552_211215_WEB.pdf |
C. Schug,
E. Morawa,
F. Geiser,
N. Hiebel,
P. Beschoner,
L. Jerg-Bretzke,
K. Weidner,
S. Steudte-Schmiedgen,
A. Borho,
M. Lieb and
Y. Erim,
"Social Support and Optimism as Protective Factors for Mental Health among 7765 Healthcare Workers in Germany during the COVID-19 Pandemic: Results of the VOICE Study",
International Journal of Environmental Research and Public Health,
vol. 18,
no. 7,
2021.
| DOI: | 10.3390/ijerph18073827 |
| Datei: | https://doi.org/10.3390/ijerph18073827 |
N. Dragano,
J. Hoebel,
B. Wachtler,
M. Diercke,
T. Lunau and
M. Wahrendorf,
"Soziale Ungleichheit in der regionalen Ausbreitung von SARS-CoV-2",
Bundesgesundheitsblatt-Gesundheitsforschung-Gesundheitsschutz,
vol. 64,
pp. 1116—1124,
2021.
| DOI: | 10.1007/s00103-021-03387-w |
R. Rubio-Acero,
J. Beyerl,
M. Muenchhoff,
M. S. Roth,
N. Castelletti,
I. Paunovic,
K. Radon,
B. Springer,
C. Nagel,
B. Boehm,
M. M. Böhmer,
A. Graf,
H. Blum,
S. Krebs,
O. T. Keppler,
A. Osterman,
Z. N. Khan,
M. Hoelscher and
A. Wieser,
"Spatially resolved qualified sewage spot sampling to track SARS-CoV-2 dynamics in Munich - One year of experience",
The Science of the total environment,
vol. 797,
pp. 149031,
2021.
Abstract:
Wastewater-based epidemiology (WBE) is a tool now increasingly proposed to monitor the SARS-CoV-2 burden in populations without the need for individual mass testing. It is especially interesting in metropolitan areas where spread can be very fast, and proper sewage systems are available for sampling with short flow times and thus little decay of the virus. We started in March 2020 to set up a once-a-week qualified spot sampling protocol in six different locations in Munich carefully chosen to contain primarily wastewater of permanent residential areas, rather than industry or hospitals. We used RT-PCR and sequencing to track the spread of SARS-CoV-2 in the Munich population with temporo-spatial resolution. The study became fully operational in mid-April 2020 and has been tracking SARS-CoV-2 RNA load weekly for one year. Sequencing of the isolated viral RNA was performed to obtain information about the presence and abundance of variants of concern in the Munich area over time. We demonstrate that the evolution of SARS-CoV-2 RNA loads (between \textless7.5 and 3874/ml) in these different areas within Munich correlates well with official seven day incidence notification data (between 0.0 and 327 per 100,000) obtained from the authorities within the respective region. Wastewater viral loads predicted the dynamic of SARS-CoV-2 local incidence about 3 weeks in advance of data based on respiratory swab analyses. Aligning with multiple different point-mutations characteristic for certain variants of concern, we could demonstrate the gradual increase of variant of concern B.1.1.7 in the Munich population beginning in January 2021, weeks before it became apparent in sequencing results of swabs samples taken from patients living in Munich. Overall, the study highlights the potential of WBE to monitor the SARS-CoV-2 pandemic, including the introduction of variants of concern in a local population.
| DOI: | 10.1016/j.scitotenv.2021.149031 |
Abstract:
Wastewater-based epidemiology (WBE) is a tool now increasingly proposed to monitor the SARS-CoV-2 burden in populations without the need for individual mass testing. It is especially interesting in metropolitan areas where spread can be very fast, and proper sewage systems are available for sampling with short flow times and thus little decay of the virus. We started in March 2020 to set up a once-a-week qualified spot sampling protocol in six different locations in Munich carefully chosen to contain primarily wastewater of permanent residential areas, rather than industry or hospitals. We used RT-PCR and sequencing to track the spread of SARS-CoV-2 in the Munich population with temporo-spatial resolution. The study became fully operational in mid-April 2020 and has been tracking SARS-CoV-2 RNA load weekly for one year. Sequencing of the isolated viral RNA was performed to obtain information about the presence and abundance of variants of concern in the Munich area over time. We demonstrate that the evolution of SARS-CoV-2 RNA loads (between \textless7.5 and 3874/ml) in these different areas within Munich correlates well with official seven day incidence notification data (between 0.0 and 327 per 100,000) obtained from the authorities within the respective region. Wastewater viral loads predicted the dynamic of SARS-CoV-2 local incidence about 3 weeks in advance of data based on respiratory swab analyses. Aligning with multiple different point-mutations characteristic for certain variants of concern, we could demonstrate the gradual increase of variant of concern B.1.1.7 in the Munich population beginning in January 2021, weeks before it became apparent in sequencing results of swabs samples taken from patients living in Munich. Overall, the study highlights the potential of WBE to monitor the SARS-CoV-2 pandemic, including the introduction of variants of concern in a local population.
R. Rubio-Acero,
J. Beyerl,
M. Muenchhoff and
et al,
"Spatially resolved qualified sewage spot sampling to track SARS-CoV-2 dynamics in Munich: One year of experience",
Sci Total Environ,
vol. 797,
2021.
| DOI: | 10.1016/j.scitotenv.2021.149031 |
S. Einhauser,
D. Peterhoff,
H. H. Niller and
et al,
"Spectrum bias and individual strengths of SARS-CoV-2 serological tests—A population-based evaluation",
Diagnostics,
vol. 11,
no. 10,
2021.
| DOI: | 10.3390/diagnostics11101843 |
| Datei: | https://doi.org/10.3390/diagnostics11101843 |
M. Borsche,
A. Balck and
et al,
"Spreading of SARS-CoV-2 Among Adult Asylum Seekers in Refugee Shelters in Germany",
Lancet,
2021.
| DOI: | 10.2139/ssrn.3889435 |
M. Geraedts,
M. Eberlein-Gonska,
R. Hecker,
K. Schneider,
I. Schroeder-Printzen and
M. Zeuner,
"Stationäre Versorgung: Empfehlungen für ein künftiges Pandemiemanagement",
Dtsch Arztebl International,
vol. 118,
no. 19—20,
pp. A-991,
2021.
C. R. Torres Reyes,
E. Steinmann,
N. Timmesfeld and
et al,
"Students in Dormitories were not major drivers of the pandemic during winter term 2020/2021: A cohort study with RT-PCR and antibody surveillance in a German university city",
COVID,
vol. 1,
no. 1,
2021.
| DOI: | 10.3390/covid1010029 |
S. Warnat-Herresthal and
et al,
"Swarm Learning for decentralized and confidential clinical machine learning",
Nature,
2021.
| DOI: | 10.1038/s41586-021-03583-3 |
T. Hempel and
et al,
"Synergistic inhibition of SARS-CoV-2 cell entry by otamixaban and covalent protease inhibitors: pre-clinical assessment of pharmacological and molecular properties",
Chemical Science,
vol. 12,
pp. 12600–12609,
2021.
| DOI: | 10.1039/D1SC01494C |
C. Wagner,
M. Griesel,
A. Mikolajewska,
A. Mueller,
M. Nothacker,
K. Kley,
M. Metzendorf,
A. Fischer,
M. Kopp,
M. Stegemann,
N. Skoetz and
F. Fichtner,
"Systemic corticosteroids for the treatment of COVID-19",
Cochrane Database of Systematic Reviews,
vol. 2021,
pp. CD014963,
2021.
| DOI: | 10.1002/14651858.CD014963 |
M. O'Hare,
H. A. B. Whitmore,
C. Marino,
L. Ramos,
S. Delgado-Tirado,
X. Hu,
N. Chmielewska,
A. Chandrahas and
D. Stahl,
"Targeting Runt-Related Transcription Factor 1 Prevents Pulmonary Fibrosis and Reduces Expression of Severe Acute Respiratory Syndrome Coronavirus 2 Host Mediators",
Am J Pathol,
vol. 191,
no. 7,
pp. 1193-1208,
2021.
| DOI: | 10.1016/j.ajpath.2021.04.006 |
M. Baldinger,
A. Heinrich,
E. Martens,
M. Dommasch,
A. Muller,
A. Siegmann,
G. Schmidt and
K. V. Laerhoven,
"TELECOVID: Remote Vital Signs Monitoring of COVID-19 Risk Patients in Home Isolation With an In-Ear Wearable",
IEEE Pervasive Computing,
vol. 20,
no. 2,
pp. 58—62,
2021.
| DOI: | 10.1109/MPRV.2021.3066825 |
G. Nouailles,
E. Wyler,
P. Pennitz,
D. Postmus,
D. Vladimirova,
J. Kazmierski,
F. Pott,
K. Dietert,
M. Muelleder,
V. Farztdinov,
B. Obermayer,
B. Sawitzki,
C. Drosten,
L. E. Sander,
N. Suttorp,
M. Ralser,
D. Beule,
A. Gruber,
C. Goffinet,
M. Landthaler,
J. Trimpert,
M. Witzenrath,
S. Wienhold and
T. Hoefler,
"Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19",
Nat Commun.2021;12(1):4869,
2021.
G. Nouailles,
E. Wyler,
P. Pennitz,
D. Postmus,
D. Vladimirova and
e. a. Kazmierski,
"Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19",
Nat Commun,
vol. 12,
pp. 4869,
2021.
| DOI: | 10.1038/s41467-021-25030-7 |
G. Nouailles,
E. Wyler,
P. Pennitz,
D. Postmus,
D. Vladimirova,
J. Kazmierski,
F. Pott,
K. Dietert,
M. Muelleder,
V. Farztdinov and
D. Stahl,
"Temporal omics analysis in Syrian hamsters unravel cellular effector responses to moderate COVID-19",
Nat Commun,
vol. 12,
no. 1,
pp. 4869,
2021.
| DOI: | 10.1038/s41467-021-25030-7 |
L. Krüger,
M. Gaeddert,
F. Tobian and
D. Stahl,
"The Abbott PanBio WHO emergency use listed, rapid, antigen-detecting point-of-care diagnostic test for SARS-CoV-2—Evaluation of the accuracy and ease-of-use",
PLOS ONE,
vol. 16,
no. 5,
2021.
| DOI: | 10.1371/journal.pone.0247918 |
| Datei: | https://doi.org/10.1371/journal.pone.0247918 |
M. Witzenrath and
W. Kuebler,
"The CypA-netics of Ventilator-induced Lung Injury",
Am J Respir Crit Care Med,
vol. 204,
no. 4,
pp. 385—387,
2021.
| DOI: | 10.1164/rccm.202104-0919ED |
M. Witzenrath and
W. Kuebler,
"The CypA-netics of Ventilator-induced Lung Injury. Am J Respir Crit Care Med",
204(4):385-387,
2021.
C. Ramirez Alvarez,
C. Kee,
A. K. Sharma,
L. Thomas,
F. I. Schmidt and
e. a. Stanifer,
"The endogenous cellular protease inhibitor SPINT2 controls SARS-CoV-2 viral infection and is associated with disease severity",
PLOS Pathogens,
vol. 17,
no. 5,
pp. e1009687,
2021.
| DOI: | 10.1371/journal.ppat.1009687 |
F. Hornung,
J. Rogal,
P. Loskill,
B. Löffler and
S. Deinhardt-Emmer,
"The Inflammatory Profile of Obesity and the Role on Pulmonary Bacterial and Viral Infections",
Int J Mol Sci,
vol. 22,
2021.
V. Clemens,
P. Beschoner,
M. Jarczok,
K. Weimer,
M. Kempf,
E. Morawa,
F. Geiser,
S. Steudte-Schmiedgen,
H. Gündel,
J. Fegert and
L. Jerg-Bretzke,
"The mediating role of COVID-19-related burden in the association between adverse childhood experiences and emotional exhaustion: Results of the egePan–VOICE study",
European Journal of Psychotraumatology,
vol. 12,
no. 1,
pp. 1976441,
2021.
| DOI: | 10.1080/20008198.2021.1976441 |
M. Hoffmann and
et al,
"The Omicron variant is highly resistant against antibody-mediated neutralization: Implications for control of the COVID-19 pandemic",
Cell,
2021.
| DOI: | 10.1016/j.cell.2021.12.032 |
J. Wachinger,
I. D. Olaru,
S. Horner and
et al,
"The potential of SARS-CoV-2 antigen-detection tests in the screening of asymptomatic persons",
Clin Microbiol Infect,
vol. 27,
no. 11,
2021.
| DOI: | 10.1016/j.cmi.2021.07.020 |
| Datei: | https://doi.org/10.1016/j.cmi.2021.07.020 |
I. Panchyrz,
S. Pohl,
J. Hoffmann,
C. Gatermann,
F. Walther,
L. Harst,
H. Held,
C. Kleber and
J. Schmitt,
"The role of university hospitals in regional health care management for coping with the COVID-19 pandemic",
Zeitschrift Für Evidenz, Fortbildung Und Qualität Im Gesundheitswesen,
vol. 167,
pp. 68—77,
2021.
| DOI: | 10.1016/j.zefq.2021.09.004 |
J. Wenzel,
J. Lampe,
H. Müller-Fielitz and
et al,
"The SARS-CoV-2 main protease Mpro causes microvascular brain pathology by cleaving NEMO in brain endothelial cells",
Nat Neurosci,
vol. 24,
no. 11,
pp. 1522-1533,
2021.
| DOI: | 10.1038/s41593-021-00926-1 |
K. Kitazawa,
S. Deinhardt-Emmer,
T. Inomata,
S. Deshpande and
C. Sotozono,
"The Transmission of SARS-CoV-2 Infection on the Ocular Surface and Prevention Strategies",
Cells,
vol. 10,
2021.
M. R. Muzoora and
et al,
"Towards FAIR Patient Reported Outcome: Application of the Interoperability Principle for Mobile Pandemic Apps",
Stud Health Technol Inform,
vol. 287,
pp. 85—86,
2021.
| DOI: | 10.3233/SHTI210315 |